Panagiotis Skendros, Georgios Germanidis, Dimitrios C Mastellos, Christina Antoniadou, Efstratios Gavriilidis, Georgios Kalopitas, Anna Samakidou, Angelos Liontos, Akrivi Chrysanthopoulou, Maria Ntinopoulou, Dionysios Kogias, Ioanna Karanika, Andreas Smyrlis, Dainora Cepaityte, Iliana Fotiadou, Nikoleta Zioga, Ioannis Mitroulis, Nikolaos K Gatselis, Charalampos Papagoras, Simeon Metallidis, Haralampos Milionis, George N Dalekos, Loek Willems, Barbro Persson, Vivek Anand Manivel, Bo Nilsson, E Sander Connolly, Simona Iacobelli, Vasileios Papadopoulos, Rodrigo T Calado, Markus Huber-Lang, Antonio M Risitano, Despina Yancopoulou, Konstantinos Ritis, John D Lambris
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 ( n = 16) or placebo ( n = 15) in addition to standard of care. AMY-101 was safe and well tolerated. Compared to placebo (8 of 15, 53.3%), a higher, albeit nonsignificant, proportion of AMY-101-treated patients (13 of 16, 81...
August 19, 2022: Science Advances